Skip to main content
Livermore
Livermore
ZHEN

LAVA Therapeutics NV

LVTXDelisted Nov 21, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001840748

LAVA Therapeutics NV was delisted on Nov 21, 2025; its insiders filed their last Form 4 on Nov 17, 2025; 21 institutions reported holding it in 13F filings for Q3 2025, worth $16.1M in total; no superinvestor held it.

13F holders, Q4 2025

Institutional positions in LAVA Therapeutics NV as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

LVTX is no longer listed, and 13F filings after Q3 2025 list far fewer holders. See Q3 2025

Institutional holders
0
−21 vs. Q3 2025
Shares held
0
−10.3M (−100.0%) vs. Q3 2025
Total value
$0
−$16.1M (−100.0%) vs. Q3 2025
New holders
0
0 more added
Sold out
21
0 more reduced

Compare with Q3 2025: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting LVTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ4 2025: 0 institutions
Q1 2021: 24 institutionsQ2 2021: 18 institutionsQ3 2021: 19 institutionsQ4 2021: 20 institutionsQ1 2022: 18 institutionsQ2 2022: 17 institutionsQ3 2022: 13 institutionsQ4 2022: 20 institutionsQ1 2023: 19 institutionsQ2 2023: 15 institutionsQ3 2023: 14 institutionsQ4 2023: 14 institutionsQ1 2024: 20 institutionsQ2 2024: 19 institutionsQ3 2024: 21 institutionsQ4 2024: 22 institutionsQ1 2025: 20 institutionsQ2 2025: 19 institutionsQ3 2025: 21 institutionsQ4 2025: 0 institutionsQ1 2026: 0 institutionsQ2 2026: 0 institutions
Value heldQ4 2025: $0
Q1 2021: $139.1MQ2 2021: $95.5MQ3 2021: $48.6MQ4 2021: $44.3MQ1 2022: $35.2MQ2 2022: $22.8MQ3 2022: $34.1MQ4 2022: $26.3MQ1 2023: $11.2MQ2 2023: $11.7MQ3 2023: $8.47MQ4 2023: $9.22MQ1 2024: $12.5MQ2 2024: $6.77MQ3 2024: $5.99MQ4 2024: $6.15MQ1 2025: $10.2MQ2 2025: $10.6MQ3 2025: $16.1MQ4 2025: $0Q1 2026: $0Q2 2026: $0
Institutions holding LVTX and their total value by quarter
QuarterHoldersValue
Q2 20260$0
Q1 20260$0
Q4 20250$0
Q3 202521$16.1M
Q2 202519$10.6M
Q1 202520$10.2M
Q4 202422$6.15M
Q3 202421$5.99M
Q2 202419$6.77M
Q1 202420$12.5M
Q4 202314$9.22M
Q3 202314$8.47M
Q2 202315$11.7M
Q1 202319$11.2M
Q4 202220$26.3M
Q3 202213$34.1M
Q2 202217$22.8M
Q1 202218$35.2M
Q4 202120$44.3M
Q3 202119$48.6M
Q2 202118$95.5M
Q1 202124$139.1M

Institutions, Q4 2025

Shares, value and share of portfolio for each institution holding LAVA Therapeutics NV; share changes are against Q3 2025.

Institutions holding LVTX in Q4 2025
InstitutionSharesValue% of portfolioChange in sharesAction
Shay Capital LLC0$00.00%−2,548,730−100.0%Sold out
Redmile Group, LLC0$00.00%−2,074,372−100.0%Sold out
BML Capital Management, LLC0$00.00%−1,970,610−100.0%Sold out
Sanofi0$00.00%−1,919,455−100.0%Sold out
Merck & Co., Inc.0$00.00%−1,149,345−100.0%Sold out
GTS Securities LLC0$00.00%−200,000−100.0%Sold out
Rangeley Capital, LLC0$00.00%−165,000−100.0%Sold out
The PNC Financial Services Group, Inc.0$00.00%−65,000−100.0%Sold out
Citadel Advisors LLC0$00.00%−53,308−100.0%Sold out
Royal Bank of Canada0$00.00%−44,348−100.0%Sold out
Lepercq De Neuflize Asset Management LLC0$00.00%−31,000−100.0%Sold out
JBF Capital, Inc.0$00.00%−23,911−100.0%Sold out
XTX Topco Ltd0$00.00%−21,727−100.0%Sold out
UBS Group AG0$00.00%−15,871−100.0%Sold out
Torno Capital, LLC0$00.00%−15,000−100.0%Sold out
Geode Capital Management, LLC0$00.00%−14,170−100.0%Sold out
Equitec Proprietary Markets, LLC0$00.00%−12,500−100.0%Sold out
TSFG, LLC0$00.00%−400−100.0%Sold out
Jones Financial Companies LLLP0$00.00%−400−100.0%Sold out
SBI Securities Co., Ltd.0$00.00%−300−100.0%Sold out
Smallwood Wealth Investment Management, LLC0$00.00%−26−100.0%Sold out